The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography

Lasers in Surgery and Medicine

Volumn 48, Issue 7, 2016, Pages 668-677

  Abri Aghdam, Kaveh ^a,b   Seidensticker, Florian ^a   Pielen, Amelie ^a   Framme, Carsten ^a   Junker, Bernd ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

aflibercept; choroidal neovascularization; ranibizumab; spectral domain optical coherence tomography

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; B SCAN; CASE STUDY; CENTRAL SUBFIELD THICKNESS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; TREATMENT RESISTANT NEOVASCULAR AGE RELATED MACULAR DEGENERATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

EID: 84983509337     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.22531     Document Type: Article

References (29)

1. Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: The Rotterdam Study. Arch Ophthalmol 1998; 116:653–658.
2. Nagineni CN, Kommineni VK, William A, Detrick B, Hooks JJ. Regulation of VEGF expression in human retinal cells by cytokines: Implications for the role of inflammation in age-related macular degeneration. J Cell Physiol 2012; 227:116–126.
3. Chen Y, Han F. Profile of ranibizumab: Efficacy and safety for the treatment of wet age-related macular degeneration. Ther Clin Risk Manag 2012; 8:343–351.
4. Trichonas G, Kaiser PK. Aflibercept for the treatment of age-related macular degeneration. Ophthalmol Ther 2013; 2:89–98.
5. Traynor K. Aflibercept approved for macular degeneration. Am J Health Syst Pharm 2012; 69:6.
6. Stewart MW, Grippon S, Kirkpatrick P. Aflibercept. Nat Rev Drug Discov 2012; 11:269–270.
7. Thomas M, Mousa SS, Mousa SA. Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmol 2013; 7:495–501.
8. Eghøj MS, Sørensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2012; 96:21–23.
9. Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 2008; 115:2199–2205.
10. Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: Tachyphylaxis or tolerance? Br J Ophthalmol 2012; 96:1–2.
11. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphy­laxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 2009; 29:723–731.
12. Wykoff CC, Brown DM, Chen E, Major JC, Croft DE, Mariani A, Wong TP; SAVE Study Group. SAVE (super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. Ophthalmic Surg Lasers Imaging Retina 2013; 44:121–126.
13. Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, Freund KB. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013; 33:1605–1612.
14. Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D, Vavvas DG, Miller JW, Kim IK. Conversion to aflibercept for chronic refractory or recurrent neovascular age related macular degeneration. Am J Ophthalmol 2013; 156:29–35.
15. Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, Hubbard GB 3rd. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol 2013; 156:23–28.
16. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119:2537–2548.
17. Christoforidis JB, Williams MM, Kothandaraman S, Kumar K, Epitropoulos FJ, Knopp MV. Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT. Curr Eye Res 2012; 37:1171–1174.
18. Van Steenkiste C, Ribera J, Geerts A, Pauta M, Tugues S, Casteleyn C, Libbrecht L, Olievier K, Schroyen B, Reynaert H, van Grunsven LA, Blomme B, Coulon S, Heindryckx F, De Vos M, Stassen JM, Vinckier S, Altamirano J, Bataller R, Carmeliet P, Van Vlierberghe H, Colle I, Morales-Ruiz M. Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology 2011; 53:1629–1640.
19. Framme C, Panagakis G, Birngruber R. Effects on choroidal neovascularization after anti-VEGF Upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography. Invest Ophthalmol Vis Sci 2010; 51:1671–1676.
20. Fassnacht-Riederle H, Becker M, Graf N, Michels S. Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Graefes Arch Clin Exp Ophthalmol 2014; 252:1705–1709.
21. Grewal DS, Gill MK, Sarezky D, Lyon AT, Mirza RG. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye (Lond) 2014; 28:895–899.
22. Ali F, Chan WC, Stevenson MR, Muldrew KA, Chakravarthy U. Morphometric analysis of angiograms of exudative lesions in age-related macular degeneration. Arch Ophthalmol 2004; 122:710–715.
23. Jørstad ØK, Faber RT, Moe MC. Initial improvements when converting eyes with treatment-resistant exudative AMD to aflibercept are substantially diminished after increasing treatment intervals from 4 to 8 weeks. Acta Ophthalmol 2015; 93:e510–e511.
24. Aghdam KA, Pielen A, Framme C, Junker B. Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results. Eur J Ophthalmol 2016; DOI: 10.5301/ejo.5000757. [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/26868007
25. Spaide RF, Koizumi H, Pozonni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 2008; 146:496–500.
26. Coscas F, Coscas G, Souied E, Tick S, Soubrane G. Optical coherence tomography identification of occult choroid neovascularization in age-related macular degeneration. Am J Ophthalmol 2007; 144:592–599.
27. Costa RA, Calucci D, Paccola L, Jorge R, Cardillo JA, Castro JC, Scott IU. Occult chorioretinal anastomosis in age-related macular degeneration: A prospective study by optical coherence tomography. Am J Ophthalmol 2005; 140:107–116.
28. Hammer M, Roggan A, Schweitzer D, Müller G. Optical properties of ocular fundus tissues: An in vitro study using the double-integrating-sphere technique and inverse Monte Carlo simulation. Phys Med Biol 1995; 40:963–978.
29. Coscas F, Coscas G, Querques G, Massamba N, Querques L, Bandello F, Souied EH. En face enhanced depth imaging optical coherence tomography of fibrovascular pigment epithelium detachment. Invest Ophthalmol Vis Sci 2012; 53:4147–4151.